C反応性蛋白検査の世界市場レポート：動向、予測、競合分析（～2031年）

世界のC反応性蛋白検査市場の将来は、クリニック、病院、研究所、介護付きヘルスケア施設、家庭市場での機会で有望視されています。世界のC反応性蛋白検査の市場規模は、2025年～2031年のCAGRが2.8%で、2031年までに推定63億米ドルに達すると予想されます。この市場の主な促進要因は、心血管疾患の頻度の上昇、ポイントオブケア・スクリーニングの導入やC反応性蛋白（CRP）検査の最先端手法の開発を目的とした政府プログラムの拡大、心血管疾患、関節リウマチ、炎症性疾患などの慢性疾患の罹患率の増加です。

• Lucintelは、心血管疾患の頻度増加により、疾患別では心血管疾患が予測期間中も引き続き最大セグメントとなる見通しです。
• 地域別では、心血管疾患罹患率の上昇、定期的な製品導入の流れ、確立された業界競合企業の存在により、北米が予測期間中最大地域であり続けると思われます。

C反応性蛋白検査市場の戦略的成長機会

C反応性蛋白検査市場は、ヘルスケアニーズの進化と技術の進歩により、著しい成長を遂げています。正確な診断と個別化医療に対する需要の高まりにより、さまざまな用途で戦略的な成長機会が生まれています。これらの機会は、C反応性蛋白検査が特定のヘルスケア課題に対処し、市場範囲を拡大し、患者の転帰を向上させるために活用できる分野を浮き彫りにします。利害関係者は、主要な用途に焦点を当てることで、これらの成長分野を特定し、それを活用することができ、市場の拡大とイノベーションを推進することができます。

• 心血管疾患リスク評価：心血管疾患リスク評価における高感度C反応性蛋白検査の利用は、大きな成長機会です。C反応性蛋白検査は心臓病に関連する低レベルの炎症を検出することができ、早期介入と個別化治療戦略を可能にします。心血管疾患は依然として世界的に罹患率と死亡率の主要な原因であるため、C反応性蛋白検査を定期的なスクリーニングと予防医療プログラムに組み込むことで、市場の大幅な成長を促進し、タイムリーな診断と管理を通じて患者の転帰を改善することができます。
• 慢性疾患管理：糖尿病、関節リウマチ、炎症性腸疾患などの慢性疾患の管理におけるC反応性蛋白検査の利用が増加しています。C反応性蛋白レベルのモニタリングは、疾患活動性の評価、治療効果の評価、治療アプローチの調整に役立ちます。この用途は、より効果的な慢性疾患管理と個別化ケアをサポートすることで成長機会をもたらします。慢性疾患の有病率の増加により、継続的なモニタリングとオーダーメイドの治療計画を提供できる信頼性の高いC反応性蛋白検査ツールの需要が高まっています。
• ポイントオブケア（POC）検査：ポイントオブケア（POC）検査ソリューションの拡大は、C反応性蛋白検査にとって大きな成長機会となります。POC検査は、従来の検査室以外で迅速な結果を提供し、診断効率と患者の利便性を向上させます。これは特に救急部、遠隔地、在宅医療環境において有益です。POC反応性蛋白検査の採用は、即座の臨床判断を促進し、中央集中型の検査インフラストラクチャーの必要性を低減することで、ヘルスケアの提供を強化することができます。
• デジタルヘルス・プラットフォームとの統合：C反応性蛋白検査を電子カルテ（EHR）や遠隔医療サービスなどのデジタルヘルス・プラットフォームと統合することで、シームレスなデータ管理や遠隔モニタリングが可能になり、成長の可能性が広がります。このような統合は、より良い治療の連携、患者の状態のリアルタイム追跡、個別化された治療戦略をサポートします。ヘルスケアにおけるデジタルソリューションの導入が進む中、C反応性蛋白検査とデジタルヘルスプラットフォームの相乗効果により、診断ワークフローと患者エンゲージメントが改善され、市場の成長が促進される可能性があります。
• 新興市場の拡大：アジアやアフリカなどの新興市場へのC反応性蛋白検査の拡大は、大きな成長機会となります。これらの地域ではヘルスケアのインフラが整備され、診断ツールへのアクセスが増加するにつれて、C反応性蛋白検査の需要が高まると予想されます。費用対効果の高い検査ソリューションを開発し、現地生産能力を確立することで、市場への参入と成長を促進することができます。これらの地域で増加する人々のヘルスケア・ニーズに対応することで、市場の大幅な拡大と世界の健康成果の向上が期待できます。

このような戦略的成長機会は、C反応性蛋白検査がさまざまな用途で市場での存在感と影響力を拡大する可能性を浮き彫りにします。心血管リスク評価、慢性疾患管理、ポイントオブケア検査、デジタルヘルス統合、新興市場に注力することで、利害関係者は進化するヘルスケアのニーズを活用し、イノベーションを推進することができます。これらの機会がC反応性蛋白検査の将来を形成し、診断と管理における役割を強化し、患者ケアの改善と市場成長に寄与しています。

C反応性蛋白検査市場の促進要因・課題

C反応性蛋白（CRP）検査市場は、技術進歩、経済要因、規制力学によって形成されるさまざまな促進要因・課題の影響を受けています。これらの市場促進要因・課題は、市場を効果的に乗り切ることを目指す利害関係者にとって極めて重要です。これらの要因の相互作用は、CRP検査ソリューションの開発、採用、成長に影響を与え、市場の軌道を形成し、戦略的意思決定に影響を与えます。

CRP検査市場の促進要因は以下の通りです：

• 技術の進歩：高感度アッセイや自動化システムなど、CRP検査技術の進歩が市場成長の原動力となっています。これらの技術革新により、CRP検査の精度、スピード、利便性が向上し、さまざまな疾患の診断やモニタリングにより効果的になっています。また、ポイントオブケアやマルチプレックス検査技術の開発により、CRP検査の用途とアクセシビリティが拡大し、臨床現場や家庭での採用拡大に寄与しています。
• 慢性疾患の有病率の上昇：心血管障害、糖尿病、自己免疫疾患などの慢性疾患の有病率の増加は、CRP検査の主要な促進要因です。これらの疾患は定期的なモニタリングと管理を必要とするため、CRP検査のような信頼性の高い診断ツールに対する需要が高まっています。この動向は、治療方針の決定や患者の転帰を改善するための効果的な炎症マーカーの必要性を強調し、CRP検査ソリューションの市場を押し上げています。
• 予防ヘルスケアへの注目の高まり：予防ヘルスケアと早期診断へのシフトがCRP検査の需要を促進しています。高感度CRP検査は、症状が出る前に心血管リスクやその他の健康状態を評価するためにますます使用されるようになっています。このような健康管理への積極的なアプローチは、早期介入と個別ケアを重視する広範なヘルスケア動向と一致し、市場成長を促進し、日常スクリーニングにおけるCRP検査の採用を増加させています。
• 新興市場におけるヘルスケア・インフラの拡大：新興市場におけるヘルスケア・インフラの改善と診断ツールへのアクセスの増加がCRP検査の成長を促進しています。アジアやアフリカなどの地域のヘルスケアシステムが発展するにつれて、CRP検査を含む診断ソリューションに対する需要が高まっています。費用対効果の高いソリューションと現地製造能力によって市場範囲を拡大することは、これらの地域で高まるヘルスケアニーズへの対応に役立ち、市場拡大に寄与します。
• デジタルヘルス技術との統合：CRP検査と電子カルテ（EHR）や遠隔医療プラットフォームなどのデジタルヘルス技術との統合は、市場成長の大きな促進要因です。この統合により、リアルタイムのデータ共有、遠隔モニタリング、個別化された治療計画が容易になります。デジタルヘルス・ソリューションが普及するにつれ、CRP検査との相乗効果により診断ワークフローと患者管理が強化され、市場拡大を後押しします。

CRP検査市場の課題は以下の通りです：

• 高度な検査ソリューションのコスト高：高感度アッセイや自動化システムなどの高度なCRP検査技術に関連する高コストが課題となっています。これらのコストは、特に低資源環境や新興市場において、アクセシビリティを制限する可能性があります。より手頃な価格の検査ソリューションや革新的な価格戦略の開発を通じてコスト障壁に対処することは、市場を拡大し、CRP検査への公平なアクセスを確保するために不可欠です。
• 規制上のハードルとコンプライアンスの問題：規制上の課題を克服し、地域によって異なる基準へのコンプライアンスを確保することは困難です。規制プロセスの複雑さは、製品の承認や市場参入のスピードに影響を与える可能性があります。企業は規制の変化を常に把握し、コンプライアンス戦略に投資してリスクを軽減し、円滑な市場参入を促進しなければなりません。
• 市場競争と飽和：CRP検査プロバイダーにとって、激しい競争と市場の飽和が課題となります。市場が成長するにつれ、新規参入企業と既存企業が市場シェアを奪い合い、価格設定や収益性に影響を及ぼす可能性があります。競争力を維持し、市場で持続的な成功を収めるためには、技術革新、性能の向上、顧客価値によって製品を差別化することが極めて重要です。

C反応性蛋白（CRP）検査市場は、市場促進要因・課題がダイナミックに絡み合って形成されています。技術の進歩、慢性疾患の増加、予防医療の動向、新興市場におけるインフラの拡大、デジタルヘルスの統合は、市場成長を促進する主な要因です。しかし、高コスト、規制のハードル、激しい競合が大きな課題となっています。利害関係者が市場を効果的に運営し、新たな動向を活用するためには、成長機会を活用しながらこれらの課題に対処することが不可欠となります。

目次

第1章 エグゼクティブサマリー

第2章 世界のC反応性蛋白検査市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析（2019年～2031年）

• マクロ経済動向（2019年～2024年）と予測（2025年～2031年）
• 世界のC反応性蛋白検査市場の動向（2019年～2024年）と予測（2025年～2031年）
• 世界のC反応性蛋白検査市場：アッセイタイプ別
  • 免疫比濁法
  • ELISA
  • 化学発光免疫測定法
  • その他
• 世界のC反応性蛋白検査市場：検出範囲別
  • hs-CRP
  • 従来型CRP
  • cCRP
• 世界のC反応性蛋白検査市場：疾患別
  • 心血管疾患
  • がん
  • 関節リウマチ
  • 炎症性腸疾患
  • 子宮内膜症
  • ループス
  • その他
• 世界のC反応性蛋白検査市場：最終用途別
  • クリニック
  • 病院
  • 研究所
  • 介護付きヘルスケア施設
  • 家庭
  • その他

第4章 市場動向と予測分析：地域別（2019年～2031年）

• 世界のC反応性蛋白検査市場：地域別
• 北米のC反応性蛋白検査市場
• 欧州のC反応性蛋白検査市場
• アジア太平洋のC反応性蛋白検査市場
• その他地域のC反応性蛋白検査市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界のC反応性蛋白検査市場の成長機会：アッセイタイプ別
  • 世界のC反応性蛋白検査市場の成長機会：検出範囲別
  • 世界のC反応性蛋白検査市場の成長機会：疾患別
  • 世界のC反応性蛋白検査市場の成長機会：最終用途別
  • 世界のC反応性蛋白検査市場の成長機会：地域別
• 世界のC反応性蛋白検査市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界のC反応性蛋白検査市場のキャパシティ拡大
  • 世界のC反応性蛋白検査市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業プロファイル

• Thermo Fisher Scientific
• F. Hoffmann-La Roche
• Danaher
• Quest Diagnostics
• Siemens Healthineers
• Abbott
• Merck
• Zoetis
• Ortho Clinical Diagnostics
• Getein Biotech

The future of the global C-reactive protein testing market looks promising with opportunities in the clinic, hospital, laboratories, assisted living healthcare facilities, and home markets. The global C-reactive protein testing market is expected to reach an estimated $6.3 billion by 2031 with a CAGR of 2.8% from 2025 to 2031. The major drivers for this market are the rising frequency of cardiovascular disorders, expanding government programs to introduce point-of-care screening and create cutting-edge methods for C-reactive protein (CRP) testing, as well as, increasing rates of chronic illnesses such as cardiovascular disease, rheumatoid arthritis, and inflammatory disorders.

• Lucintel forecasts that, within the disease category, cardiovascular diseases will remain the largest segment over the forecast period due to the rise in the frequency of cardiovascular disorders.
• In terms of regions, North America will remain the largest region over the forecast period due to rising cardiovascular disease incidence, a regular stream of product introductions, and the existence of established industry competitors.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the C-Reactive Protein Testing Market

The C-reactive protein testing market is undergoing significant transformation due to several emerging trends. These trends reflect advancements in technology, changing healthcare priorities, and increasing demand for personalized medicine. These trends are crucial for stakeholders aiming to navigate the evolving landscape of CRP testing and capitalize on new opportunities within the market.

• High-Sensitivity CRP Testing: High-sensitivity CRP (hs-CRP) testing is becoming increasingly prominent due to its ability to detect lower levels of inflammation associated with chronic diseases like cardiovascular conditions. This trend is reshaping preventive care by enabling early detection and risk assessment, leading to timely interventions and better management of diseases. As awareness grows, hs-CRP tests are being integrated into routine health check-ups, enhancing their role in proactive healthcare strategies.
• Point-of-Care Testing: The rise of point-of-care (POC) CRP testing is revolutionizing diagnostic practices by providing rapid results in diverse settings, from clinics to home care. This trend is driven by the demand for faster diagnostics and improved patient convenience. POC testing reduces turnaround times, facilitates immediate clinical decisions, and improves patient satisfaction. It is particularly beneficial in managing acute conditions where timely intervention is critical.
• Technological Advancements: Technological advancements in CRP testing, including automation and miniaturization of testing devices, are streamlining the diagnostic process. Innovations such as multiplex assays and integrated systems are enhancing accuracy, efficiency, and ease of use. These developments are making CRP testing more accessible and cost-effective, benefiting both healthcare providers and patients by improving diagnostic workflows and reducing operational costs.
• Integration with Digital Health: The integration of CRP testing with digital health technologies, such as electronic health records (EHRs) and telemedicine platforms, is transforming the management of inflammatory conditions. Digital integration enables seamless data sharing, remote monitoring, and personalized care plans. This trend supports better patient management by facilitating real-time tracking of CRP levels and enhancing communication between patients and healthcare providers.
• Increased Focus on Chronic Disease Management: There is a growing emphasis on using CRP testing for managing chronic diseases, including diabetes, obesity, and autoimmune disorders. This trend reflects the broader healthcare shift towards personalized and preventive care. CRP testing helps in monitoring disease progression, evaluating treatment efficacy, and tailoring therapeutic approaches. As chronic disease prevalence rises, CRP testing is becoming a key tool in comprehensive disease management strategies.

These emerging trends are reshaping the C-reactive protein testing market by enhancing diagnostic capabilities, improving accessibility, and aligning with the broader shift toward personalized and preventive healthcare. The continued evolution of CRP testing reflects a growing commitment to early detection and effective management of inflammatory conditions, ultimately benefiting patients and healthcare systems globally.

Recent Developments in the C-Reactive Protein Testing Market

The C-reactive protein testing market has experienced notable developments recently, driven by technological advancements, shifting healthcare priorities, and increasing demand for precise diagnostics. These developments are impacting various aspects of C-reactive protein testing, from methodology to market accessibility, and are shaping the future of inflammation detection and disease management.

• Advancement in Testing Technology: Recent advancements in C-reactive protein testing technology include the development of high-sensitivity assays and more accurate analytical platforms. These innovations enhance the ability to detect low levels of inflammation, improving early diagnosis and monitoring of chronic conditions. The introduction of automated systems and multiplex assays has also streamlined testing processes, increasing efficiency and reliability in clinical settings.
• Expansion of Point-of-Care Solutions: The growth of point-of-care (POC) C-reactive protein testing solutions has been a significant development, providing rapid and convenient testing options outside traditional laboratories. These solutions are particularly beneficial in emergency settings and remote areas, allowing for immediate results and prompt clinical decision-making. The expansion of POC C-reactive protein testing reflects the increasing demand for accessible and efficient diagnostic tools.
• Integration with Digital Health Platforms: C-reactive protein testing is increasingly being integrated with digital health platforms, including electronic health records (EHRs) and telemedicine services. This integration facilitates real-time data sharing, remote monitoring, and better patient management. The synergy between C-reactive protein testing and digital health technologies supports more coordinated care and enhances the overall efficiency of healthcare delivery.
• Growth in Market Accessibility: Efforts to improve market accessibility for C-reactive protein testing, particularly in emerging economies, have been notable. This includes the development of cost-effective testing kits and expansion of distribution networks. As healthcare infrastructure improves in regions such as India and China, the availability of C-reactive protein testing is increasing, leading to broader adoption and early detection of inflammatory conditions.
• Focus on Personalized Medicine: The shift towards personalized medicine is influencing C-reactive protein testing practices, with a growing emphasis on tailoring diagnostic and treatment approaches to individual patient profiles. C-reactive protein testing is being used to better understand patient-specific inflammation patterns and customize treatment plans. This trend aligns with the broader movement towards more individualized and effective healthcare strategies.

These developments are significantly impacting the C-reactive protein testing market by enhancing diagnostic capabilities, improving accessibility, and aligning with contemporary healthcare trends. The focus on advanced technology, point-of-care solutions, and personalized medicine is driving the evolution of C-reactive protein testing, ultimately contributing to better patient outcomes and more efficient healthcare delivery.

Strategic Growth Opportunities for C-Reactive Protein Testing Market

The C-reactive protein testing market is witnessing significant growth due to evolving healthcare needs and technological advancements. Strategic growth opportunities are emerging across various applications, driven by the increasing demand for precise diagnostics and personalized medicine. These opportunities highlight areas where C-reactive protein testing can be leveraged to address specific healthcare challenges, expand market reach, and enhance patient outcomes. By focusing on key applications, stakeholders can identify and capitalize on these growth areas to drive market expansion and innovation.

• Cardiovascular Disease Risk Assessment: The use of high-sensitivity C-reactive protein testing for cardiovascular disease risk assessment is a major growth opportunity. C-reactive protein tests can detect low levels of inflammation linked to heart disease, enabling early intervention and personalized treatment strategies. As cardiovascular diseases remain a leading cause of morbidity and mortality globally, integrating C-reactive protein testing into routine screenings and preventive care programs can drive significant market growth and improve patient outcomes through timely diagnosis and management.
• Chronic Disease Management: C-reactive protein testing is increasingly being utilized in managing chronic diseases such as diabetes, rheumatoid arthritis, and inflammatory bowel disease. Monitoring C-reactive protein levels helps in assessing disease activity, evaluating treatment effectiveness, and adjusting therapeutic approaches. This application presents a growth opportunity by supporting more effective chronic disease management and personalized care. The growing prevalence of chronic conditions enhances the demand for reliable C-reactive protein testing tools that can offer continuous monitoring and tailored treatment plans.
• Point-of-Care (POC) Testing: The expansion of point-of-care (POC) testing solutions represents a significant growth opportunity for C-reactive protein testing. POC tests provide rapid results outside traditional laboratory settings, improving diagnostic efficiency and patient convenience. This is particularly beneficial in emergency departments, remote areas, and home care settings. The adoption of POC C-reactive protein testing can enhance healthcare delivery by facilitating immediate clinical decisions and reducing the need for centralized laboratory infrastructure.
• Integration with Digital Health Platforms: Integrating C-reactive protein testing with digital health platforms, such as electronic health records (EHRs) and telemedicine services, offers growth potential by enabling seamless data management and remote monitoring. This integration supports better coordination of care, real-time tracking of patient conditions, and personalized treatment strategies. As healthcare increasingly embraces digital solutions, the synergy between C-reactive protein testing and digital health platforms can drive market growth by improving diagnostic workflows and patient engagement.
• Emerging Markets Expansion: Expanding C-reactive protein testing into emerging markets, such as those in Asia and Africa, presents a significant growth opportunity. As healthcare infrastructure improves and access to diagnostic tools increases in these regions, the demand for C-reactive protein testing is expected to rise. Developing cost-effective testing solutions and establishing local manufacturing capabilities can facilitate market entry and growth. Addressing the healthcare needs of growing populations in these regions can drive substantial market expansion and improve global health outcomes.

These strategic growth opportunities highlight the potential for C-reactive protein testing to expand its market presence and impact across various applications. By focusing on cardiovascular risk assessment, chronic disease management, point-of-care testing, digital health integration, and emerging markets, stakeholders can capitalize on evolving healthcare needs and drive innovation. These opportunities are shaping the future of C-reactive protein testing, enhancing its role in diagnosis and management, and contributing to improved patient care and market growth.

C-Reactive Protein Testing Market Driver and Challenges

The C-reactive protein (CRP) testing market is influenced by a range of drivers and challenges shaped by technological advancements, economic factors, and regulatory dynamics. These drivers and challenges are crucial for stakeholders aiming to navigate the market effectively. The interplay of these factors impacts the development, adoption, and growth of CRP testing solutions, shaping the market's trajectory and influencing strategic decisions.

The factors responsible for driving the c-reactive protein testing market include:

• Technological Advancements: Advancements in CRP testing technology, including high-sensitivity assays and automated systems, are driving market growth. These innovations enhance the accuracy, speed, and convenience of CRP testing, making it more effective for diagnosing and monitoring various conditions. The development of point-of-care and multiplex testing technologies also expands CRP testing applications and accessibility, contributing to increased adoption across clinical and home settings.
• Rising Prevalence of Chronic Diseases: The increasing prevalence of chronic diseases, such as cardiovascular disorders, diabetes, and autoimmune conditions, is a major driver for CRP testing. As these conditions require regular monitoring and management, the demand for reliable diagnostic tools like CRP tests grows. This trend emphasizes the need for effective inflammation markers to guide treatment decisions and improve patient outcomes, boosting the market for CRP testing solutions.
• Growing Focus on Preventive Healthcare: A shift towards preventive healthcare and early diagnosis is fueling the demand for CRP testing. High-sensitivity CRP tests are increasingly used for assessing cardiovascular risk and other health conditions before symptoms develop. This proactive approach to health management aligns with broader healthcare trends emphasizing early intervention and personalized care, driving market growth and increasing the adoption of CRP testing in routine screenings.
• Expanding Healthcare Infrastructure in Emerging Markets: Improvements in healthcare infrastructure and increasing access to diagnostic tools in emerging markets are driving the growth of CRP testing. As healthcare systems in regions such as Asia and Africa evolve, the demand for diagnostic solutions, including CRP testing, rises. Expanding market reach through cost-effective solutions and local manufacturing capabilities helps address the growing healthcare needs in these regions, contributing to market expansion.
• Integration with Digital Health Technologies: The integration of CRP testing with digital health technologies, such as electronic health records (EHRs) and telemedicine platforms, is a significant driver of market growth. This integration facilitates real-time data sharing, remote monitoring, and personalized treatment plans. As digital health solutions become more prevalent, the synergy with CRP testing enhances diagnostic workflows and patient management, supporting market expansion.

Challenges in the c-reactive protein testing market are:

• High Costs of Advanced Testing Solutions: The high costs associated with advanced CRP testing technologies, such as high-sensitivity assays and automated systems, pose a challenge. These costs can limit accessibility, particularly in low-resource settings or emerging markets. Addressing cost barriers through the development of more affordable testing solutions and innovative pricing strategies is essential for broadening market reach and ensuring equitable access to CRP testing.
• Regulatory Hurdles and Compliance Issues: Navigating regulatory requirements and ensuring compliance with varying standards across different regions can be challenging. The complexity of regulatory processes may impact the speed of product approvals and market entry. Companies must stay abreast of regulatory changes and invest in compliance strategies to mitigate risks and facilitate smoother market access.
• Market Competition and Saturation: Intense competition and market saturation pose challenges for CRP testing providers. As the market grows, new entrants and existing players compete for market share, which can impact pricing and profitability. Differentiating products through innovation, improved performance, and customer value is crucial for maintaining a competitive edge and achieving sustained market success.

The C-reactive protein (CRP) testing market is shaped by a dynamic interplay of drivers and challenges. Technological advancements, rising chronic disease prevalence, preventive healthcare trends, expanding infrastructure in emerging markets, and digital health integration are key drivers fueling market growth. However, high costs, regulatory hurdles, and intense competition present significant challenges. Addressing these challenges while leveraging growth opportunities will be essential for stakeholders to navigate the market effectively and capitalize on emerging trends.

List of C-Reactive Protein Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies C-reactive protein testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the C-reactive protein testing companies profiled in this report include-

• Thermo Fisher Scientific
• F. Hoffmann-La Roche
• Danaher
• Quest Diagnostics
• Siemens Healthineers
• Abbott
• Merck
• Zoetis
• Ortho Clinical Diagnostics
• Getein Biotech

C-Reactive Protein Testing by Segment

The study includes a forecast for the global C-reactive protein testing market by assay type, detection range, disease, end use, and region.

C-Reactive Protein Testing Market by Assay Type [Analysis by Value from 2019 to 2031]:

• Immunoturbidimetric Assay
• ELISA
• Chemiluminescence Immunoassay
• Others

C-Reactive Protein Testing Market by Detection Range [Analysis by Value from 2019 to 2031]:

• hs-CRP
• Conventional CRP
• cCRP

C-Reactive Protein Testing Market by Disease [Analysis by Value from 2019 to 2031]:

• Cardiovascular Diseases
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Endometriosis
• Lupus

C-Reactive Protein Testing Market by End Use [Analysis by Value from 2019 to 2031]:

• Clinics
• Hospitals
• Laboratories
• Assisted Living Healthcare Facilities
• Home
• Others

C-Reactive Protein Testing Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the C-Reactive Protein Testing Market

The C-reactive protein (CRP) testing is a crucial diagnostic tool used to detect inflammation and monitor various health conditions, including infections and chronic diseases. The market for CRP testing has evolved significantly in recent years due to advancements in technology, increased awareness of inflammatory diseases, and rising demand for rapid and accurate diagnostic tools. This evolution is characterized by varying developments across key global markets, including the United States, China, Germany, India, and Japan. Each country has demonstrated unique advancements and trends impacting the overall CRP testing landscape.

• United States: In the U.S., CRP testing has seen significant technological advancements with the introduction of high-sensitivity CRP (hs-CRP) assays, which are increasingly used for cardiovascular risk assessment. The integration of these tests into routine health screenings has become more prevalent due to growing awareness of heart disease and preventive health measures. Additionally, the market has been boosted by innovations in point-of-care testing, enhancing accessibility and convenience for both patients and healthcare providers.
• China: China's CRP testing market is expanding rapidly due to the increasing prevalence of chronic diseases and a growing emphasis on early diagnosis. Recent developments include advancements in testing technology and the establishment of local manufacturing facilities for CRP diagnostic kits, reducing costs and improving availability. The Chinese government's healthcare reforms and investments in diagnostic infrastructure are also contributing to the market's growth, making CRP testing more accessible across various regions.
• Germany: Germany has been at the forefront of integrating advanced CRP testing technologies into clinical practice. The introduction of rapid and automated CRP testing systems has streamlined the diagnostic process in hospitals and clinics. Additionally, Germany's strong focus on research and development in medical diagnostics has led to innovations in CRP testing methodologies and increased precision, further driving the adoption of these tests in both acute and chronic care settings.
• India: In India, the CRP testing market is experiencing growth driven by increased healthcare awareness and improvements in diagnostic infrastructure. The rise in lifestyle-related diseases and the need for cost-effective diagnostic solutions have led to the adoption of affordable CRP testing kits. Efforts to enhance healthcare accessibility in rural areas have also contributed to the expansion of CRP testing services, supported by government initiatives and partnerships with international organizations.
• Japan: Japan's CRP testing market is characterized by the integration of cutting-edge technology and a strong emphasis on precision medicine. The country has seen advancements in high-sensitivity CRP testing and automated analyzers, which are being adopted in both clinical and research settings. The Japanese healthcare system's focus on early detection and personalized treatment has driven the development and use of advanced CRP testing methods, improving patient outcomes and diagnostic accuracy.

Features of the Global C-Reactive Protein Testing Market

Market Size Estimates: C-reactive protein testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: C-reactive protein testing market size by various segments, such as by assay type, detection range, disease, end use, and region in terms of value ($B).

Regional Analysis: C-reactive protein testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different assay type, detection range, disease, end use, and regions for the C-reactive protein testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the C-reactive protein testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the C-reactive protein testing market by assay type (immunoturbidimetric assay, elisa, chemiluminescence immunoassay, and others), detection range (hs-CRP, conventional CRP, and cCRP), disease (cardiovascular diseases, cancer, rheumatoid arthritis, inflammatory bowel disease, endometriosis, lupus, and others), end use (clinics, hospitals, laboratories, assisted living healthcare facilities, home, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global C-Reactive Protein Testing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global C-Reactive Protein Testing Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global C-Reactive Protein Testing Market by Assay Type
  • 3.3.1: Immunoturbidimetric Assay
  • 3.3.2: ELISA
  • 3.3.3: Chemiluminescence Immunoassay
  • 3.3.4: Others
• 3.4: Global C-Reactive Protein Testing Market by Detection Range
  • 3.4.1: hs-CRP
  • 3.4.2: Conventional CRP
  • 3.4.3: cCRP
• 3.5: Global C-Reactive Protein Testing Market by Disease
  • 3.5.1: Cardiovascular Diseases
  • 3.5.2: Cancer
  • 3.5.3: Rheumatoid Arthritis
  • 3.5.4: Inflammatory Bowel Disease
  • 3.5.5: Endometriosis
  • 3.5.6: Lupus
  • 3.5.7: Others
• 3.6: Global C-Reactive Protein Testing Market by End Use
  • 3.6.1: Clinics
  • 3.6.2: Hospitals
  • 3.6.3: Laboratories
  • 3.6.4: Assisted Living Healthcare Facilities
  • 3.6.5: Home
  • 3.6.6: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global C-Reactive Protein Testing Market by Region
• 4.2: North American C-Reactive Protein Testing Market
  • 4.2.1: North American Market by Disease: Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, and Others
  • 4.2.2: North American Market by End Use: Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, and Others
• 4.3: European C-Reactive Protein Testing Market
  • 4.3.1: European Market by Disease: Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, and Others
  • 4.3.2: European Market by End Use: Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, and Others
• 4.4: APAC C-Reactive Protein Testing Market
  • 4.4.1: APAC Market by Disease: Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, and Others
  • 4.4.2: APAC Market by End Use: Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, and Others
• 4.5: ROW C-Reactive Protein Testing Market
  • 4.5.1: ROW Market by Disease: Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, and Others
  • 4.5.2: ROW Market by End Use: Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global C-Reactive Protein Testing Market by Assay Type
  • 6.1.2: Growth Opportunities for the Global C-Reactive Protein Testing Market by Detection Range
  • 6.1.3: Growth Opportunities for the Global C-Reactive Protein Testing Market by Disease
  • 6.1.4: Growth Opportunities for the Global C-Reactive Protein Testing Market by End Use
  • 6.1.5: Growth Opportunities for the Global C-Reactive Protein Testing Market by Region
• 6.2: Emerging Trends in the Global C-Reactive Protein Testing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global C-Reactive Protein Testing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global C-Reactive Protein Testing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Thermo Fisher Scientific
• 7.2: F. Hoffmann-La Roche
• 7.3: Danaher
• 7.4: Quest Diagnostics
• 7.5: Siemens Healthineers
• 7.6: Abbott
• 7.7: Merck
• 7.8: Zoetis
• 7.9: Ortho Clinical Diagnostics
• 7.10: Getein Biotech